With the 2026 ASCO Annual Meeting just days away, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal sit down for a rapid-fire, “mouth-to-butt” preview of the most practice-altering abstracts hitting the floor in Chicago. Armed with top-line press releases and early data, the team highlights their top three high-stakes selections across the entire GI tract.

Key previews include:

  • The Upper GI Blockbusters (Tim’s Picks): Updated HORIZON-GEA data showing why HER2/PD-1 bispecific synergy doesn’t care about baseline PD-L1 expression; a compliance deep-dive from the Matterhorn trial; and the arrival of IsaBrin (an EGFR/HER3 bispecific ADC) moving the needle in second-line squamous cell esophageal cancer.
  • The Midgut & Plenary Hype (Udhayvir’s Picks): Front-row seats for RESOLUTE-302, the monumental plenary session showcasing deruxantrib doubling overall survival (13 months vs. 6.7 months) in second-line RAS-mutant pancreatic cancer. Plus, the PHITE-302 trial proving frontline pemigatinib works for FGFR2-rearranged cholangiocarcinoma despite notorious accrual challenges.
  • Below-the-Belt Tech & Wild West De-escalation (Nick’s Picks): The highly anticipated late-breaking PUMP trial testing adjuvant hepatic artery infusion (HAI) pumps for colorectal liver metastases. Then, a massive look at China’s Abstract 3502, confirming that MSI-High colorectal patients who hit a Complete Clinical Response can safely stop maintenance immunotherapy and maintain a 100% 3-year overall survival rate.
  • The Sci-Fi Future: A look outside the box at the Archer trial in lung cancer—utilizing a prophylactic peptide vaccine to train the immune system to short-circuit targeted therapy resistance mutations before they occur.

Chapters:

00:00 Welcome and ASCO Preview

00:46 Top Three Picks Setup

01:28 HORIZON GEA HER2 Triplet

03:55 Matterhorn DFLOT Completion

06:11 IsaBrin for ESCC Second Line

08:10 RESOLUTE-302 RAS Inhibitor

13:12 PHITE 302 Pemigatinib Frontline

20:10 PUMP Trial Hepatic Infusion

24:02 MSI-High CRC Stop PD-1

29:15 Archer Vaccine vs Resistance

33:30 Closing Thoughts and Chicago

You can find us on X:Gut Onc Lab (@TheGutOncLab) / X

Contributors:

Dr. Nicholas Hornstein

Dr. Nicholas Hornstein, MD, PhD, is a gastrointestinal medical oncologist and Assistant Professor Northwell Health.

Dr. Timothy Brown

Dr. Timothy Brown, MD, MSCE, is a gastrointestinal medical oncologist and Assistant Professor at UT Southwestern.

Dr. Udhayvir Grewal

Dr. Udhayvir Grewal, MD, MBBS, is a gastrointestinal medical oncologist and Assistant Professor at Emory University School of Medicine.